1. Scrip
  2. >>Business

Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate

Biotech Targets Triple-Negative Breast Cancer and Lymphoma

 
• By Andrew McConaghie

The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.

Merck KGaA Darmstadt
Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech.

Merck KGaA has licensed to French biotech Diaccurate a PAM inhibitor candidate which could treat a broad range of tumors, including triple-negative breast cancer (TNBC) and relapsed/refractory B-cell and T-cell lymphomas.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.